tiprankstipranks
Trending News
More News >
BioView Ltd. (IL:BIOV)
:BIOV
Israel Market

Bio View (BIOV) Price & Analysis

Compare
0 Followers

BIOV Stock Chart & Stats


Financials

BIOV FAQ

What was BioView Ltd.’s price range in the past 12 months?
BioView Ltd. lowest stock price was 19.50 and its highest was 36.00 in the past 12 months.
    What is BioView Ltd.’s market cap?
    BioView Ltd.’s market cap is 26.78M.
      When is BioView Ltd.’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were BioView Ltd.’s earnings last quarter?
      BioView Ltd. released its earnings results on Aug 19, 2021. The company reported 0 earnings per share for the quarter, the consensus estimate of N/A by 0.
        Is BioView Ltd. overvalued?
        According to Wall Street analysts BioView Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does BioView Ltd. pay dividends?
          BioView Ltd. pays a Notavailable dividend of 200 which represents an annual dividend yield of N/A. See more information on BioView Ltd. dividends here
            What is BioView Ltd.’s EPS estimate?
            BioView Ltd.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does BioView Ltd. have?
            BioView Ltd. has 136,653,000 shares outstanding.
              What happened to BioView Ltd.’s price movement after its last earnings report?
              BioView Ltd. reported an EPS of 0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same N/A.
                Which hedge fund is a major shareholder of BioView Ltd.?
                Currently, no hedge funds are holding shares in IL:BIOV

                Company Description

                BioView Ltd.

                Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. Its products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH samples in real-time; and Allegro Plus, an automatic fluorescent imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an imaging and analysis platform that include an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; Solo Touch Workstation, a stand-alone workstation with advanced review and analysis tools; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases. Bio-View Ltd has a partnership agreement with ANGLE plc to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 2000 and is headquartered in Rehovot, Israel.
                Similar Stocks
                Company
                Price & Change
                Follow
                Allmed Solution
                Elbit Medical Technologies Ltd
                Human Xt
                Erika B-Cure
                MediPress Health-Limited Partnership Partnership Units
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis